Allogene Highlights CAR T Clinical Progress in Kidney Cancer at SITC Meeting

• Allogene Therapeutics will present renal cell carcinoma clinical experience from its TRAVERSE study at SITC on Nov. 5, 2026.
• Preclinical findings on its DLL3/CD70 dual CAR T candidate for small cell lung cancer and other neuroendocrine tumors will follow Nov. 6.
• The findings suggest selecting the genomic integration site can improve CAR T cells’ tumor control.
• Pairing DLL3 and CD70 targeting enhanced resistance to immune-mediated rejection, supporting Dagger technology’s potential use across additional off-the-shelf cell therapies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allogene Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611030800PRIMZONEFULLFEED9868523) on November 03, 2026, and is solely responsible for the information contained therein.